Stage II Prostate Adenocarcinoma AJCC v7 Clinical Trial
Official title:
Phase II Trial of Hypofractionated Proton Beam Therapy in Men With Localized Prostate Adenocarcinoma
Verified date | May 2024 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies the side effects and how well hypofractionated proton beam radiation therapy works in treating patients with prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Status | Active, not recruiting |
Enrollment | 241 |
Est. completion date | June 1, 2025 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed diagnosis of adenocarcinoma of the prostate within one year of study entry; evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson - History/physical examination with digital rectal examination of the prostate within 90 days prior to registration - Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material demonstrating Gleason score 2-7 within 365 days of registration - Clinical stage T1-2b (American Joint Committee on Cancer [AJCC] 7th edition) and PSA < 20 ng/mL within 90 days prior to registration; PSA should not be obtained within 10 days after prostate biopsy - Zubrod performance status 0-1 within 90 days prior to registration - Patient must be able to provide study-specific informed consent prior to study entry - Willingness and ability to complete the EPIC questionnaire Exclusion Criteria: - Prior or concurrent invasive malignancy (except non-melanomatous skin cancer or lymphomatous/hematogenous malignancy) unless continually disease free for a minimum of 5 years - Evidence of distant metastases - Regional lymph node involvement - Previous prostatectomy, cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer - Previous pelvic radiation or prostate brachytherapy - Active and severe medical co-morbidity defined as follows: unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months, transmural myocardial infarction within the last 6 months, acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration, chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration, hepatic insufficiency resulting in clinical jaundice, active inflammatory bowel disease (Crohn's disease or ulcerative colitis), diagnosed connective tissue disorder, or congenital coagulation defects (patients on medical therapy with Coumadin or other blood thinning agents are eligible for participation) |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cumulative incidence of late grade 2 or greater gastrointestinal (GI) toxicity | The cumulative incidence of late grade 2 or greater GI toxicity will be estimated with a 95% confidence interval. | Up to 2 years post-treatment | |
Secondary | Rates of acute toxicity | Rates of acute toxicity will be assessed. | Within 90 days of treatment initiation | |
Secondary | Rate of late toxicity | Rate of late toxicity will be determined. | Up to 5 years post-treatment | |
Secondary | Change in health related quality of life (HRQOL) as assessed by the Expanded Prostate Cancer Index Composite (EPIC) Utilization of Sexual Medications/Devices, and Medical history/conditions questionnaire | Change in HRQOL will be evaluated. | Baseline to up to 5 years | |
Secondary | Incidence of rising prostate-specific antigen (PSA) | Incidence of rising PSA will be assessed. | At 5 years | |
Secondary | Rate of local failure by biopsy | Rate of local failure by biopsy will be evaluated. | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01787331 -
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
|
Phase 2 | |
Completed |
NCT02326805 -
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
|
Phase 2 | |
Completed |
NCT02830165 -
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
|
N/A | |
Active, not recruiting |
NCT03541850 -
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
|
Phase 2 |